IOVA — IOVANCE BIOTHERAPEUTICS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1425205 ·
Last close
$7.53
Market Cap
$3.48B
52W High
$15.37
52W Low
$2.08
ADV30
14,226,309
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 99,313,000 55,718,000 -51,905,000 -47,315,000 915,531,000 110,768,000 179,486,000
Mar 2026 71,430,000 28,932,000 -81,043,000 -79,045,000 925,665,000 196,508,000 203,911,000
Dec 2025 86,771,000 43,660,000 -73,460,000 -71,904,000 913,170,000 163,078,000 214,587,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-264,182,000
Investing CF
$-44,869,000
Financing CF
$287,851,000
CapEx
$-32,213,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.53
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,901,890,000
Inventory
$55,590,000
Receivables
$81,758,000
ST Investments
$116,935,000
EBIT TTM
$-296,166,000
Pretax Income TTM
$-293,776,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$378,983,008
EBITDA
$-192,107,008
Free Cash Flow
$-187,794,752
Enterprise Value
$3,390,221,312
Total Cash
$297,673,984
Total Debt
$46,003,000
Shares Out
462,655,151
Trailing EPS
$-0.49
Book Value
$1.62
ROE
-40.4%
ROA
-20.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 263,502,000 -398,213,000 -390,978,000 913,170,000 214,587,000 698,583,000 -302,408,000
Dec 2024 164,070,000 -395,278,000 -372,177,000 910,426,000 200,021,000 710,405,000 -352,977,000
Dec 2023 1,189,000 -460,559,000 -444,037,000 780,351,000 195,738,000 584,613,000 -361,820,000
Dec 2022 0 -398,878,000 -395,893,000 663,982,000 164,344,000 499,638,000 -292,757,000

TTM Snapshot

Revenues TTM
$324,969,000
NetIncome TTM
$-289,517,000
OpCashFlow TTM
—
Assets (Latest)
$915,531,000
Forward EPS
$-0.17

Max Pain — expiry 2026-12-18

max pain strike: $7.50 · spot: $7.48 · call oi: 17,445 · put oi: 8,563
Expected Move to 2026-12-18: ±$1.45 (19.39%) — implied range $6.03 – $8.93 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RLAY Relay Therapeutics, Inc. $3.64B $16.47 —
TARS Tarsus Pharmaceuticals, Inc. $3.86B $78.20 —
CRSP CRISPR Therapeutics AG $3.89B $40.15 —
ADMA ADMA BIOLOGICS, INC. $3.02B $13.63 —
VCEL Vericel Corp $2.95B $57.88 —

News headlines (Yahoo Finance, 1h cache)

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb
2026-11-16 15:14 · Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
2026-11-12 21:05 · Yahoo
Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More
2026-11-09 08:33 · Yahoo
Iovance Biotherapeutics (IOVA) Q3 Earnings Sharpen Focus On Margin Recovery
2026-11-07 06:13 · Yahoo
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
2026-11-06 12:31 · Yahoo
Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122 Million ...
2026-11-06 11:10 · Yahoo
Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
2026-11-05 22:16 · Yahoo
Iovance (IOVA) Q3 2026 Earnings Call Transcript
2026-11-05 21:34 · Yahoo
Iovance Biotherapeutics Q3 Earnings Call Highlights
2026-11-05 21:14 · Yahoo
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 12:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.